s-217622
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Aug 3, 2022 (NCT05305547)
Timeline
Indications
Mechanism of action
- 3C-like proteaseINHIBITOR
3C-like protease inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cnc(Cn2c(=O)[nH]/c(=N\c3cc4cn(C)nc4cc3Cl)n(Cc3cc(F)c(F)cc3F)c2=O)n1- Mol. weight
- 531.89 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5183847 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06775730 | Phase 1 | Dec 30, 2024 | Shionogi |
| NCT06161688 | Phase 2 | Jan 1, 2024 | Shionogi, University of California, San Francisco |
| NCT05897541 | Phase 3 | Jun 9, 2023 | Shionogi |
| NCT05605093 | Phase 3 | Dec 15, 2022 | National Institute of Allergy and Infectious Diseases (NIAID), University of Copenhagen, University of Minnesota |
| NCT05409911 | Phase 1 | Sep 13, 2022 | Shionogi |
| NCT05363215 | Phase 1 | Aug 10, 2022 | Shionogi |
| NCT05305547 | Phase 3 | Aug 3, 2022 | National Institute of Allergy and Infectious Diseases (NIAID), Shionogi |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shionogi | For profit | 6 | 5 | 3 | 2022 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2022 |
5 organizations
Page 1 / 1